André J, Vic P, Humeau C, Rochefort H
Mol Cell Endocrinol. 1977 Sep;8(3):225-41. doi: 10.1016/0303-7207(77)90094-6.
Ethidium bromide (EB), an intercalating drug, has been shown to prevent the in vitro interaction of the estrogen receptor (R) with DNA (André et al., 1976). We have now studied the effect of this drug on the nuclear translocation of R in order to determine whether DNA integrity is needed for this translocation. In a cell-free reconstituted system made of purified nuclei and cytosol, the pretreatment of nuclei by EB prevented approximately half of the R nuclear translocation, but was unable to extract more than 17% of the E2-R previously translocated. A series of indirect evidences suggests that EB inhibits the nuclear translocation of R by interacting with nuclear DNA. The degree of the inhibition was related to the amount of drug bound to nuclei and was in agreement with the degree of ultrastructural modifications of chromatin. R was not irreversibly altered by the drug. The EB inhibition was only observed with DNA-containing particles and with estrogen receptor able to bind to DNA. In surviving uteri the drug also inhibited the R nuclear translocation. These resuts indicate two types of nuclear translocation of R, one sensitive and the other resistant to EB, and suggest that DNA is required for the EB-sensitive translocation.
溴化乙锭(EB)是一种嵌入性药物,已被证明可在体外阻止雌激素受体(R)与DNA的相互作用(安德烈等人,1976年)。我们现在研究了这种药物对R核转位的影响,以确定这种转位是否需要DNA完整性。在由纯化的细胞核和细胞质组成的无细胞重组系统中,用EB预处理细胞核可阻止约一半的R核转位,但无法提取超过先前转位的E2-R的17%。一系列间接证据表明,EB通过与核DNA相互作用抑制R的核转位。抑制程度与结合到细胞核的药物量有关,并且与染色质超微结构修饰的程度一致。R并未被该药物不可逆地改变。仅在含DNA的颗粒和能够结合DNA的雌激素受体中观察到EB抑制作用。在存活的子宫中,该药物也抑制R的核转位。这些结果表明R的核转位有两种类型,一种对EB敏感,另一种对EB有抗性,并表明DNA是EB敏感转位所必需的。